Download PDF
Hamostaseologie 1999; 19(02): 68-76
DOI: 10.1055/s-0038-1660382
Übersichtsarbeiten/Review Articles
Schattauer GmbH

Myokardinfarkt und Thrombolyse

K. Huber
1   Universitätsklinik für Innere Medizin II (Kardiologie) der Universität Wien (Leiter: Univ.-Prof. Dr. Gerald Maurer)
,
Ute Priglinger
1   Universitätsklinik für Innere Medizin II (Kardiologie) der Universität Wien (Leiter: Univ.-Prof. Dr. Gerald Maurer)
,
Mariani Nikfardjam
1   Universitätsklinik für Innere Medizin II (Kardiologie) der Universität Wien (Leiter: Univ.-Prof. Dr. Gerald Maurer)
,
G. Maurer
1   Universitätsklinik für Innere Medizin II (Kardiologie) der Universität Wien (Leiter: Univ.-Prof. Dr. Gerald Maurer)
› Author Affiliations
Further Information

Publication History

Publication Date:
27 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Thrombolysetherapie stellt wegen ihrer ubiquitären Zugänglichkeit und einfachen Applikationsweise einen Meilenstein in der Behandlung des akuten Myokardinfarktes dar. Mit dem natürlichen Gewebeplasminogenaktivator (t-PA) und seinen biochemisch modifizierten Varianten, die zumindest theoretisch bessere Eigenschaften aufweisen als die Muttersubstanz, stehen uns heute äußerst potente Fibrinolytika zur Verfügung. Andere neue Präparate wie z.B. Staphylokinase, Pro-Urokinase, oder der Vampir-Fledermaus-Plasminogen-Aktivator DSPA-alpha-1 stehen an der Schwelle zur kommerziellen klinischen Nutzung. Im vorliegenden Artikel wird besonders auf weitere Verbesserungsmöglichkeiten der Thrombolysetherapie, wie z. B. die Verkürzung der Zeitdauer Infarktbeginn - Lysebeginn, die Verbesserung der TIMI-Grad-3-Flußrate und die Optimierung der antithrombotischen Begleittherapie, eingegangen.

Schlüsselwörter

Myokardinfarkt - Thrombolyse - Fibrinolytika - Verbesserungen
 

  • Literatur

  • 1 Ambrose J.A, Almeida O.D, Sharma S.K, Torre S.R, Marmur J.D, Israel D.H, Ratner D.E, Weiss M.B, Hjemdahl-Monsen C.E, Myler R.K, Moses J, Unterecker W.J, Garrett J.S, Cowley M.J, Anwar A, Sobolski J. Adjunct thrombolytic therapy during angioplasty for ischemic rest angina: Results of the TAUSA trial. Circulation 1994; 90: 69-77.
    CrossrefPubMedGoogle Scholar
  • 2 Anderson J.L, Becker R.C, Sorensen S.G, Karagounis L.A, Browne K.F, Shah P.K, Morris D.C, Fintel D.J, Mueller H.S, Ross A.M, Hall S.M, Asians J.C, Doorey A.J, Grines C.L, Moreno F.L, Marder V.J. for the TEAM-3 Investigators: Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. J Am Coll Cardiol 1992; 20: 753-66.
    CrossrefPubMedGoogle Scholar
  • 3 Anderson J.L, Sorensen S.G, Moreno F.L, Hackworthy R.A, Browne K.F, Dale H.T. et al. for the TEAM-2 Study Investigators. Multi-center patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation 1991; S3: 126-40.
    PubMedGoogle Scholar
  • 4 Antiplatelet. Antiplatelet Trialists Collaborators. Collaborative overview of randomized trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 159-68.
    CrossrefPubMedGoogle Scholar
  • 5 Antman E.M. for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
    CrossrefPubMedGoogle Scholar
  • 6 Antman E.M. for the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B Trial. Circulation 1996; 94: 911-21.
    CrossrefPubMedGoogle Scholar
  • 7 Antman E.M, Giugliano R.P, McCabe C.H, Gibson M, Adgey A.J.J, Ghali M, Coussement P, Anderson K.M, Scherer J, Van de Werf F, and Braunwald E. Abciximab (ReoPro®) potentiates thrombolysis in ST elevation myocardial infarction: Results of TIMI 14 Trial. J Am Coll Cardiol 1998; 31: 191 A (Abstract 842-1).
    CrossrefPubMedGoogle Scholar
  • 8 Bär F.W, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spiecker M, Macaya C, Hanssen M, Heras M, Boland J.P, Morice M.C, Dunn F.G, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen A.J, Klein W, Windeier J, Hopkins G, Barth H, and von Fisenne M.J.M. Comparison od saruplase and alteplase in acute myocardial infarction: the Study in Europe with Saruplase and Alteplase in Myocardial Infarction (SESAM). Am J Cardiol 1997; 79: 727-32.
    CrossrefPubMedGoogle Scholar
  • 9 Barbash G.I, Hod H, Roth A, Miller H.I, Rath S, Zahav Y.H, Modan M, Zivelin A, Laniado S, and Seligsohn U. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct artery after thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1989; 64: 1231-5.
    CrossrefPubMedGoogle Scholar
  • 10 Barbash G.I, White H.D, Modan M, and Van de Werf F. for the Investigstors of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. J Am Coll Cardiol 1993; 22: 707-13.
    CrossrefPubMedGoogle Scholar
  • 11 Barlow G.H, Lazer L, Rueter A, and Tribby I. 1977. Production of plasminogen activators by culture cell techniques. Academic Press; New York:
    Google Scholar
  • 12 Bleich S.D, Nichols T.C, Schumacher R.R, Cooke D.H, Tate D.A, and Teichman S.L. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990; 66: 1412-7.
    CrossrefPubMedGoogle Scholar
  • 13 Braunwald E. The open-artery theory is alive and well - again. N Engl J Med 1993; 329: 1650-2.
    CrossrefPubMedGoogle Scholar
  • 14 Brodgen R.N, Speight T.M, and Avery G.S. Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses. Drugs 1973; 5: 357-445.
    CrossrefPubMedGoogle Scholar
  • 15 Califf R.M, White H.D, Van de Werf F, Sadowski Z, Armstrong P.W, Vahanian A, Simoons M.L, Simes R.J, Lee K.L, and Topol E.J. for the GUSTO-I Investigators. One-year results from the Global Utilization of Streptokinaase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial. Circulation 1996; 94: 1233-8.
    CrossrefPubMedGoogle Scholar
  • 16 Cannon C.P, Antman E.M, Walls R, and Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thrombos Throm-bolys 1994; 1: 27-34.
    PubMedGoogle Scholar
  • 17 Cannon C.P, McCabe C.H, Diver D.J, Herson S, Grenne R.M, Shah P.K, Sequeira R.F, Leya F, Kirshenbaum J.M, Magorien R.D, Palmeri S.T, Davis V, Gibson C.M, Poole W.K, and Braunwald E. and the TIMI 4 Investigators. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistre-plase and combination thrombolytic therapy for acute myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 4 trial. J Am Coll Cardiol 1994; 24: 1602-10.
    CrossrefPubMedGoogle Scholar
  • 18 Cannon C.P, McCabe C.H, Gibson M.C, Adgey J.A, Sweiger M.J, Sequeira M.J, Sequeira R.F, Muller H.S, McCluskey E.R, Fox N.L, Van de Werf F, and Braunwald E. TNK-tissue plasminogen activator compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial. Circulation 1997; 96: 1-206. Abstract.
    PubMedGoogle Scholar
  • 19 Cederholm-Williams S.A, de Cook F, Lijnen H.R, and Collen D. Kinetics of the reactions between streptokinase, plasmin and alpha-2antiplasmin. Eur J Biochem 1979; 100: 125-32.
    CrossrefPubMedGoogle Scholar
  • 20 Collen D. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Collen D. Engineered staphylokinase variants with reduced immunogenicity. Fibrinol Proteol 1998; 12: 59-65.
    PubMedGoogle Scholar
  • 22 Collen D, de Cock F, Vanlinthout I, Declerck P.J, Lijnen H.R, and Stassen J.M. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992; 6: 232-42.
    PubMedGoogle Scholar
  • 23 Collen D, Silence K, Demarsin E, De Mol M, and Lijnen H.R. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 203-13.
    PubMedGoogle Scholar
  • 24 European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383-9.
    CrossrefPubMedGoogle Scholar
  • 25 Every N.R, Parsons L.S, Hlatky M, Martin J.S, and Weaver W.D. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996; 335: 1253-61.
    CrossrefPubMedGoogle Scholar
  • 26 Fibrinolytic Therapy Trialists’ (FFT) Collaborative Group. indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994; 343: 311-22.
    CrossrefPubMedGoogle Scholar
  • 27 Gibbons R.J, Holmes D.R, Reeder G.S, Bailey K.R, Hopfenspirger M.R, and Gersh B.J. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328: 685-91.
    CrossrefPubMedGoogle Scholar
  • 28 GISSI-2:a factorial randomized trial od alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
    PubMedGoogle Scholar
  • 29 Glick A, Kornowski R, Michowich Y, Koifman B, Roth A, Laniado S, and Keren G. Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol 1996; 77: 1145-8.
    CrossrefPubMedGoogle Scholar
  • 30 Grines C.L, Browne K.F, Marco J, Rothbaum D, Stone G.W, O’Keefe J, Overlie P, Donohue B, Chelliah N, Timmis G.C, Vliestra R.E, Strzelecki M, Puchrowivz-Ochocki S, and O’Neill W.W. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993; 328: 673-9.
    CrossrefPubMedGoogle Scholar
  • 31 Gulba D.C, Bode C, Runge M.S, and Huber K. Thrombolytic agents - an updated overview. Fibrinol Proteol 1998; 12: 39-58.
    PubMedGoogle Scholar
  • 32 Gulba D.C, Praus M, and Witt W. DSPA alpha - properties of the plasminogen activators of the vampire bat desmodus rotundus. Fibrinolysis 1995; 9: 91-6.
    PubMedGoogle Scholar
  • 33 Gulba D.C, Tanswell P, Dechend R, Sosada M, Weis A, Waigand J, Uhlich F, Hauck S, Jost S, Raffenbleul W, Lichtlen P.R, and Dietz R. Sixty-minute alteplase protocoll: A new accelerated rcombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction. J Am Coll Cardiol 1997; 30: 1611-17.
    CrossrefPubMedGoogle Scholar
  • 34 Giinzler W.A, Steffens G.J, Otting F, Buse G, and Flohé L. Structural relationship between human high and low molecular mass urokinase. Hoppe-Seyler’s Z Physiol Chem 1982; 363: 133-41.
    PubMedGoogle Scholar
  • 35 Gurwitz J.H, Goldberg R.J, and Gore J.M. Coronary thrombolysis for the elderly?. J American Medical Association 1991; 265: 1720-3.
    CrossrefPubMedGoogle Scholar
  • 36 The GUSTO Angiographic Investigators. the effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after myocardial infarction. N Engl J Med 1993; 329: 1615-22.
    CrossrefPubMedGoogle Scholar
  • 37 The GUSTO Investigators. An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
    CrossrefPubMedGoogle Scholar
  • 38 GUSTO Ha. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Globais Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Ha Investigators. Circulation 1994; 90: 1631-7.
    CrossrefPubMedGoogle Scholar
  • 39 GUSTO lib. The Global Use of Strategies to Open Occlude Coronary Arteries (GUSTO) lib Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996; 335: 775-82.
    CrossrefPubMedGoogle Scholar
  • 40 Harpel P.C, Chang T-S, and Verderber E. Tissue-plasminogen activator and urokinase mediate the binding of glu-plasminogen to plasma fibrin. I. Evidence for new binding sites in plasma-degraded fibrin. J Biol Chem 1985; 260: 4432-40.
    PubMedGoogle Scholar
  • 41 Herlitz J, Hartford M, Blohm M, Risenfors M, Karlsson B.W, and Holmberg S. Effect of a media campaign on delay times and ambulance use in suspected acute myocardial infarction. Am J Cardiol 1989; 64: 90-3.
    CrossrefPubMedGoogle Scholar
  • 42 Huber K. Die koronare Reokklusion - ein ungelöstes Problem der Thrombolysethera-pie des akuten Herzinfarktes. Innere Medizin 1993; 48: 316-23.
    PubMedGoogle Scholar
  • 43 Huber K. Biochemistry, pharmacokinetics and dynamics of single- and two-chain urokinase. In: The Textbook of Coronary Thrombosis and Thrombolysis. Becker R.C. (ed.) Boston, Dordrecht, London: Kluwer Academic Publishers; 1997: 247-55.
    Google Scholar
  • 44 Huber K, Beckmann R, Rauscha F, Probst P, Kaindl F, and Binder B.R. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator. Z Kardiol 1993; 82: 194-9.
    PubMedGoogle Scholar
  • 45 Huber K, Kirchheimer J.C, and Binder B.R. Rapid isolation of high molecular weight urokinase from native human urine. Thromb Haemost 1982; 47: 197-202.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Huber K, Nikfardjam M, Christ G, Gottsauner-Wolf M, Müllner M, and Gulba D. Acute coronary syndromes: recent achievements and future aspects. Fibrinol Proteol 1998; 12: 67-89.
    PubMedGoogle Scholar
  • 47 Husain S.S, Gurewich V, and Lipinski B. Purification and partial characterization of a single-chain-high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1982; 220: 31-38.
    PubMedGoogle Scholar
  • 48 International Joint Efficacy Comparison of Thrombolytics (INJECT). Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction: trial to investigate equivalence. Lancet 1995; 346: 329-35.
    CrossrefPubMedGoogle Scholar
  • 49 ISIS-2 collaborative group: randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;349-60.
    PubMed
  • 50 ISIS-3:a randomized comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and aspirin plus heparin vs aspirin alone among 41,299 cases of suspected myocardial infarction. Lancet 1992; 339: 753-70.
    CrossrefPubMedGoogle Scholar
  • 51 Karnash S.L, Granger C.B, White H.D, Woodlief L.H, Topol E.J, and Califf R.M. for the GUSTO-I Investigators. Treating menstruating women with thrombolytic therapy: insights from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial. J Am Coll Cardiol 1995; 26: 1651-6.
    CrossrefPubMedGoogle Scholar
  • 52 Keyt B, Paoni N.F, Refino C.J, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, and Bennett W.F. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-4.
    CrossrefPubMedGoogle Scholar
  • 53 Larsen G.R, Timony G.A, Horgan PGKMB, Henson K.S, Angus L.B, and Stoudemire J.B. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem 1991; 266: 8156-61.
    PubMedGoogle Scholar
  • 54 LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759-66.
    CrossrefPubMedGoogle Scholar
  • 55 Lee K.L, Woodlief L.H, Topol E.J, Weaver W.D, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, and Califf R.M. for the GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41 021 patients. Circulation 1995; 91: 1659-68.
    CrossrefPubMedGoogle Scholar
  • 56 Lijnen H.R, van Hoef B, de Cock F, Okada K, Ueshima S, Matsuo O, and Collen D. On the mechansim of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-32.
    PubMedGoogle Scholar
  • 57 Lijnen H.R, van Hoef B, Vandenbossche L, and Collen D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis 1992; 6: 214-25.
    PubMedGoogle Scholar
  • 58 Lincoff A.M, and Topol E.J. Trickle down thrombolysis. J Am Coll Cardiol 1993; 21: 1396-8.
    CrossrefPubMedGoogle Scholar
  • 59 Lincoff A.M, and Topol E.J. 1996. Thrombolytic therapy. Lippincott-Raven Publishers; Philadelphia:
    Google Scholar
  • 60 MacCallum A.G, Stafford P.J, Jones C, Vincent R, Perez-Avila C, and Chamberlain D.A. Reduction in hospital time to thrombolytic therapy by audit of policy guidelines. Eur Heart J 1990; 11: 48-52.
    PubMedGoogle Scholar
  • 61 Mahaffey K.W, Granger C.B, Toth C.A, White H.D, Stebbins A.L, Barbash G.I, Vahanian A, Topol E.J, and Califf R.M. for the GUSTO-I Investigators. Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol 1997; 30: 1606-10.
    CrossrefPubMedGoogle Scholar
  • 62 Marder V.J, and Sherry S. Thrombolytic therapy: current status. N Engl J Med 1988; 318: 1512-20.
    CrossrefPubMedGoogle Scholar
  • 63 Martin U, Bader R, Böhm E, Kohnert U, von Möllendorf E, Fischer S, and Sponer G. BM 06.022:a novel recombinant plasminogen activator. Cardiovasc Drug Rev 1993; 11: 299-311.
    CrossrefPubMedGoogle Scholar
  • 64 Martin U, Fischer S, and Sponer G. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis. J Am Coll Cardiol 1993; 22: 914-20.
    CrossrefPubMedGoogle Scholar
  • 65 Mathey D.G, Schofer H, Sheehan F.H. et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985; 55: 878-82.
    CrossrefPubMedGoogle Scholar
  • 66 Michels R, Hoffmann H, Windeier J, Barth H, and Hopkins G. on behalf of the SUT AMI Investigators. A double-blind multicenter comparison of the efficacy and safety of Saruplase and Urokinase in the treatment of acute myocardial infarction: report of the SUTAMI Study Group. J Thrombos Throm-bolys 1995; 2: 117-24.
    PubMedGoogle Scholar
  • 67 Neches R.B, and Goldfarb A.M. Thrombolytic therapy after cardiopulmonary resuscitation in acute myocardial infarction. Am J Cardiol 1993; 71: 258-61.
    CrossrefPubMedGoogle Scholar
  • 68 Neuhaus K-L, Tebbe U, Gottwick M, Weber M.A.J, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser K-D, Huhmann W, Hoepp H-W, Alber G, Sheikhzadeh A, and Schneider B. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German activator rokinase study (GAUS). J Am Coll Cardiol 1988; 12: 581-7.
    CrossrefPubMedGoogle Scholar
  • 69 O’Connor C.M, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N, Heard III M, Mittler B, Collins G, Navetta F, Leimberger J, Lee K, and Califf R. for the DU CCS Group. A randomized trial of in ta ven o us heparin in conjunction with anistreplase (anisolated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 1994; 23: 11-18.
    CrossrefPubMedGoogle Scholar
  • 70 Ohman M, Kleiman N, Gacioch G, Worley S, Navetta F.I, Talley D, Anderson H.V, Ellis S.G, Cohen M, Sprioggs D, Miller M, Keraiakes D, Yakubov S, Kitt M.M, Sigmon K.N, Califf R.M, Krucoff M.W, and Topol E.J. for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein Ilb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled dose-ranging trial. Circulation 1997; 95: 846-54.
    CrossrefPubMedGoogle Scholar
  • 71 Okada K, Lijnen H.R, Moreau H, Vanderschueren S, and Collen D. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator. Thromb Haemost 1996; 76: 857-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Pannell R, and Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism of selective fibrinolytic effect. Blood 1986; 67: 1215-23.
    PubMedGoogle Scholar
  • 73 Paoni N.F, Keyt B.A, Refino C.J. et al. A slow clearing, fibirn-specific, PAI resistant variant of t-PA (T103N, KHRR 296-299 AAAA). Thromb Haemost 1993; 70: 307-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 PRIMI Trial Study Group. Randomized double-blind trial of recombinant prouro-kinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8.
    PubMedGoogle Scholar
  • 75 Raschke R.A, Reilly B.M, Guiclry J.R, Fontana J.R, and Srinivas S. The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram. Arch Int Med 1993; 119: 874-81.
    PubMedGoogle Scholar
  • 76 Rawles J. on behalf of the GREAT Group. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994; 23: 1-5.
    CrossrefPubMedGoogle Scholar
  • 77 Reimer K.A, Lowe J.E, Rasnussen M.M, and Jennings R.B. The wave front phenomenon of ischemic cell death: I. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977; 56: 786-93.
    CrossrefPubMedGoogle Scholar
  • 78 Ribeiro E.E, Silva L.A, Carneiro R, D’Oliveira L.G, Gasquez A, Amino J.G, Tavares J.R, Petrizzo A, Torossian S, and Duprat-Filho R. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993; 22: 376-80.
    CrossrefPubMedGoogle Scholar
  • 79 Rijken D.C, Hoylarts M, and Collen D. Fibrinolytic properties of one-cahin and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-5.
    PubMedGoogle Scholar
  • 80 Ross A.M. Reperfusion therapy for myocardial infarction: principles established, application still evolving. Fibrinoi Proteol 1998; 12: 1-3.
    PubMedGoogle Scholar
  • 81 Ross A.M, Coyne K.S, Moreyra E, Reiner J.S, Greenhouse S.W, Walker P.L, Simoons M.L, Draoui Y.C, Califf R.M, Topol E.J, Van de Werf F, and Lundergan C.F. for the GUSTO-I Angiographie Investigators. Extended mortality benefit of early postinfarction reperfusion. Circulation 1998; 97: 1549-56.
    CrossrefPubMedGoogle Scholar
  • 82 Scholz K.H, Tebbe U, Herrmann C, Wojcik J, Lingen R, Chemnitius J.M, Brune S, and Kreuzer H. Frequency of complications of cardiopulmonary resuscitation after thrombolysis during acute myocardial infarction. Am J Cardiol 1992; 69: 724-8.
    CrossrefPubMedGoogle Scholar
  • 83 Smalling R.W, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, and Seals A. and the RAPID Investigators. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91: 2725-32.
    CrossrefPubMedGoogle Scholar
  • 84 Smith R.A.G, Dupe R.J, English P.D, and Grenn J. Fibrinolysis with acyl-enzymes: new approach to thrombolytic therapy. Nature 1981; 290: 505-8.
    CrossrefPubMedGoogle Scholar
  • 85 Steffens G.J, Giinzler W.A, Hennies H-H. et al. Molecular characterization of human low molecular weight mass urokinase obtained from recombinant E.coli bacteria. In: Book. Davidson J.F, Donati M.B, and Coccheri S. (eds) Edinburgh: Churchill Livingstone; 1985: 217-20.
    Google Scholar
  • 86 Stone G.W, Grines C.L, Browne K.F, Marco J, Rothbaum D, O’Keefe J, Hartzler G.O, Overlie P, Donohue B, Chelliah N, Timmis G.C, Vlietstra R, Strzelecki M, Puchrowicz-Ochocki S, and O’Neill W.W. Predictors of inhospital and 6-months outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) Trial. J Am Coll Cardiol 1995; 25: 370-7.
    CrossrefPubMedGoogle Scholar
  • 87 Tebbe U, Windeier J, Boesl I, Hoffmann H, Wojcik J, Ashmawy M, Schwarz E.R, von Loewis of Menar P, Rosemeyer P, Hopkins C.l, and Barth H. Thrombolysis with recombinant unglycossylated single-chain urokina-se-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS Study). J Am Coll Cardiol 1995; 26: 365-73.
    CrossrefPubMedGoogle Scholar
  • 88 The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators.. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-23.
    CrossrefPubMedGoogle Scholar
  • 89 The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-5.
    CrossrefPubMedGoogle Scholar
  • 90 The TIMI HIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI HIB trial. Circulation 1994; 89: 1545-56.
    CrossrefPubMedGoogle Scholar
  • 91 TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; Phase I findings. N Engl J Med 1985; 312: 932-6.
    PubMedGoogle Scholar
  • 92 Torr-Brown S.R, and Sobel B.E. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993; 72: 413-21.
    CrossrefPubMedGoogle Scholar
  • 93 Vanderschuren S, Barrios L, Kerdsinchai P, Van den Heuvei P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, and Van de Werf F. for the STAR trial group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-9.
    CrossrefPubMedGoogle Scholar
  • 94 Weston C.F.M, and Avery P. Thrombolysis following pre-hospital cardiopulmonary resuscitation. Int J Cardiol 1992; 37: 195-8.
    CrossrefPubMedGoogle Scholar
  • 95 White H.D, and Van de Werf F. Thrombolysis for acute myocardial infarction. Circulation 1998; 97: 1632-46.
    CrossrefPubMedGoogle Scholar
  • 96 Wiman B, and Wallen P. Structural relationship between »glutamic acid« and »lysine« forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography. Eur J Biochem 1975; 50: 489-94.
    CrossrefPubMedGoogle Scholar
  • 97 Woodfield S.L, Lundergan C.F, Reiner J.S, Greenhouse S.W, Thompson M.A, Rohrbeck S.C, Deychak Y, Simoons M.L, Califf R.M, Topol E.J, and Ross A.M. for the GUSTO-I Angiographic Investigators. Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 1996; 28: 1661-9.
    CrossrefPubMedGoogle Scholar
  • 98 Young E, Prins M.H, Levine M.N, and Hirsh J. Heparin binding to plasma proteins. An important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-43.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 99 Zijlstra F, de Boer M.J, Hoorntje J.C, Reiffers S, Reiher J.H, and Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-4.
    CrossrefPubMedGoogle Scholar